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 Statement of Clinical Relevance 
 
 
 The results of this study show that a high YY1 gene signature (characterized by 
coordinate elevated expression of transcription factor YY1 and putative YY1 target genes) within 
serous epithelial ovarian cancers is associated with enhanced response to taxane-based 
chemotherapy and improved survival.  If confirmed in a prospective study, these results have 
important implications for the potential future use of individualized therapy in treating patients 
with ovarian cancer.  Identification of the YY1 gene signature profile within a tumor prior to 
initiation of chemotherapy may provide valuable information about the anticipated response of 
these tumors to taxane-based drugs, leading to better informed decisions regarding 
chemotherapeutic choice.    
 ABSTRACT 
 
Purpose. Survival of ovarian cancer patients is largely dictated by their response to 
chemotherapy, which depends on underlying molecular features of the malignancy. We 
previously identified YIN YANG 1 (YY1) as a gene whose expression is positively correlated 
with ovarian cancer survival. Herein we investigated the mechanistic basis of this association. 
Experimental design. Epigenetic and genetic characteristics of YY1 in serous epithelial ovarian 
cancer (SEOC) were analyzed along with YY1 mRNA and protein. Patterns of gene expression 
in primary SEOC and in the NCI60 database were investigated using computational methods.  
YY1 function and modulation of chemotherapeutic response in vitro was studied using siRNA 
knockdown.   
Results. Microarray analysis showed strong positive correlation between expression of YY1 
and genes with YY1 and transcription factor E2F binding motifs in SEOC and in the NCI60 
cancer cell lines. Clustering of microarray data for these genes revealed that high YY1/E2F3 
activity positively correlates with survival of patients treated with the microtubule stabilizing drug 
paclitaxel.  Increased sensitivity to taxanes, but not to DNA crosslinking platinum agents, was 
also characteristic of NCI60 cancer cell lines with a high YY1/E2F signature. YY1 knockdown in 
ovarian cancer cell lines results in inhibition of anchorage-independent growth, motility and 
proliferation, but also increases resistance to taxanes, with no effect on cisplatin sensitivity.  
Conclusions. These results, together with the prior demonstration of augmentation of 
microtubule-related genes by E2F3, suggest that enhanced taxane sensitivity in tumors with 




 Epithelial ovarian cancer is the leading cause of death from gynecologic malignancies in 
the United States, with 21,650 new cases and 15,520 deaths expected this year alone 
(http://www.cancer.gov). Most cases are metastatic when diagnosed and are treated with 
systemic chemotherapy consisting of a combination of taxane, a microtubule stabilizing agent, 
and platinum drugs that form DNA and protein crosslinks. The majority of women with advanced 
stage ovarian cancer succumb within five years due to recurrence of chemoresistant disease. 
One of the major obstacles to improving patient survival is the lack of understanding regarding 
the molecular characteristics of ovarian malignancies that contribute to chemotherapeutic 
response. Delineating these features may provide the means to improve patient prognosis in the 
future by allowing treatment strategies to take into account the likelihood that a given 
malignancy will respond to treatment favorably based on its underlying molecular phenotype. 
 
 Previously we reported that elevated YIN YANG 1 (YY1) expression is positively 
correlated with enhanced survival of ovarian cancer patients based on gene expression 
microarray analysis (1). This finding was confirmed using an independent ovarian cancer 
microarray gene expression dataset (2), supporting that YY1 plays a significant role in ovarian 
cancer prognosis. We therefore hypothesized that elevated YY1 expression is functionally 
involved in positively influencing the response to chemotherapeutic agents for women 
diagnosed with epithelial ovarian cancer. YY1 encodes a GLI-Krüppel type zinc finger protein 
that is ubiquitously expressed and conserved among vertebrates (3-7), with functional homologs 
present in Drosophila (8). YY1 protein has divergent cellular functions, including the ability to 
activate and repress gene transcription, modulate the function of other proteins, and affect 
chromatin structure (9). YY1 transcription and function is also tied to progression of the cell 
cycle (10-13), implicating a possible role in carcinogenesis (9, 14). YY1 was previously shown to 
 function synergistically with E2F2 and E2F3 to activate target gene transcription in a molecular 
complex bridged by the Ring1- and YY1-binding protein (RYBP) (12). Such interactions facilitate 
the transcriptional activation of target genes that are involved in cell cycle progression and 
mitosis (15).  
 
 Based on analysis of two independent sets of microarray data, including our serous 
epithelial ovarian cancer data and the NCI60 dataset comprising 59 cell lines of multiple cancer 
types, we show herein that YY1 in association with E2F upregulates target genes having YY1 
and E2F binding motifs. We further sought to understand the reasons underlying the differences 
in survival of ovarian cancer patients with respect to expression of YY1. We found that high YY1 
activity correlates with sensitivity to taxanes and better prognosis of ovarian cancer patients. 
Furthermore, we uncovered an association between YY1 and E2F that regulates transcription of 
genes encoding proteins involved in microtubule-associated functions. 
 
 MATERIALS AND METHODS 
 
Tissues and cell lines. 
 All tissues were obtained with consent and used with approval from the Duke University 
Institutional Review Board. Human conceptal tissues were provided by the NIH-supported 
Laboratory of Human Embryology at the University of Washington, Seattle. Malignant and 
normal ovarian tissues and lymphocytes were provided by the Gynecologic Oncology Tumor 
Bank at Duke University Medical Center. Ovarian cancer cell lines were cultured in RPMI 1640 
media (Invitrogen Co. Carlsbad, CA) with 10% fetal bovine serum (Invitrogen) and 1% penicillin-
streptomycin solution (Invitrogen) in a 37ºC humidified incubator with 5% atmospheric CO2. 
 
Microarray datasets. 
 Microarray data (Affymetrix U133A genechips) was generated and normalized as 
previously described (1). This microarray data includes 12 serous borderline tumors, 12 early 
stage (stage I/II) serous epithelial ovarian cancers, 24 advanced stage (III/IV) serous ovarian 
cancers (living ≥7y post diagnosis), 33 advanced stage serous ovarian cancers (living ≤3y post-
diagnosis) and 7 advanced stage recurrent serous epithelial ovarian cancers. The 
clinicopathological features of this patient population were described previously (1). We used 
microarray gene expression data from an additional 79 advanced serous epithelial ovarian 
cancers for external validation. This dataset is derived from previously published data (16) by 
excluding samples overlapping with the above dataset (1). NCI60 data from Affymetrix U95Av2 
microarrays was also used (http://www.dtp.nci.nih.gov/).   
 
Transcription factor binding motif analysis.  
 We retrieved gene promoter sequences, as annotated by RefSeq, from -1,200 bases 
upstream to 200 bases downstream of the transcription start site from the hg17 assembly of the 
 human genome from the UC Santa Cruz Genome Browser (17, 18). We mapped those 
sequences to the probes on the Affymetrix microarrays via the common Gene IDs provided by 
RefSeq and NetAffx. We then scanned each of the promoter sequences for binding motifs using 
TRANSFAC version 8.2 (19). We discarded the hits whose scores did not exceed the cutoffs 
recommended in the minSUM_good74 file provided in the TRANSFAC database. Based on the 
probe annotation for RefSeq IDs, a TRANSFAC annotation file was generated for the Affymetrix 
probes. 
 
Correlation to YY1.  
 Affymetrix U133A YY1 probes with Log2 expression values >7 in at least one sample 
were used for ovarian tumor dataset analysis following REDuction of Invariant probes (REDI; 
kindly performed by Expression Analysis, Inc., Durham, NC; Table SI). REDI allowed us to 
exclude probes that were defined as "not responsive" or " invariant”, although this did not cause 
a significant difference in results. YY1 probes used for the calculation of correlation coefficients 
included 200047_s_at and 201901_s_at and expression values from these probes were 
averaged. Probe 891_at in the U95Av2 probe set, annotated as “best match” with either of the 
above two probes, was used in both the NCI60 dataset and the external validation dataset. 
Pearson product-moment correlation coefficients to YY1 were calculated for all the probes using 
the correlation (CORREL) function in EXCEL for each dataset. 
 
Clustering and heat maps.  
 Clustering was performed using Cluster 3.0, available from the website, 
http://rana.lbl.gov/EisenSoftware.htm. Genes for clustering were selected as described above. 
Prior to clustering, gene expression was median-centered and normalized in Cluster 3.0. Heat 
maps for expression microarray data were made with Java TreeView 
(http://jtreeview.sourceforge.net/). Heat maps for correlation coefficients and E2F3 signature 
 probability data were made using the statistical computing and graphics environment, R 
(http://www.rproject.org/). We filtered genes with low expression in the majority of tumors by 
using log2 transformed expression values and retained those with high expression (≥ 7) in one 
or more tumors (20). Of 22,215 probes on the Affymetrix U133A genechip, approximately 
13,000 met this criterion. The top 250 YY1 positively correlated genes that contain both YY1 
and E2F binding motifs according to TRANSFAC analysis (V$YY1_Q6 and V$E2F1_Q3, 
respectively) were selected for clustering after median centered normalization using Cluster. For 
NCI60 U95Av2 dataset, top 150 probes were selected and clustering was conducted in the 
same way. 
 
E2F3 signature probability.  
 The E2F3 overexpression gene signature was previously developed using microarray 
data from recombinant adenovirus-infected primary mammary epithelial cells (16). This 
microarray dataset was also used to analyze transcriptional regulation of microtubule related 
genes by E2F3. 
 
Gene Set Enrichment Analysis (GSEA).  
 GSEA was performed using the GSEA software available from 
http://www.broad.mit.edu/gsea/ (21). The Affymetrix U133 probe lists having Gene Ontology 
designations of “microtubule” (GO#5874) or “microtubule associated complex” (GO#5875) were 
generated from the annotation files available from the Affymetrix website 
(http://www.affymetrix.com/). Enrichment of these gene lists was examined between ten control 
and nine E2F3 overexpressing samples (16). False Discovery Rates (q) < 0.25 were considered 
biologically relevant. 
 
YY1 knockdown.  
  Cells from the BG1 and HEY ovarian cancer cell lines were seeded into a 24-well plate 
at a density of 1x105 cells/well followed by transfection with 5 nM of either control non-silencing 
siRNA oligos or YY1-specific siRNA oligos (Qiagen; Valencia, CA) using HiPerfect reagent 
(Qiagen) according to the manufacturer’s recommendations. YY1-specific siRNA oligo 
sequences were as follows: siRNA target 1 sequence: GAC GAC GAC TAC ATT GAA CAA; 
siRNA 1 sense oligo: r(CGA CGA CUA CAU UGA ACA A)dTdT; siRNA 1 antisense oligo: 
r(UUG UUC AAU GUA GUC GUC G)dTdC; siRNA 2 target sequence: AAC CTG AAA TCT CAC 
ATC TTA; siRNA 2 sense oligo: r(CCU GAA AUC UCA CAU CUU A)dTdT; siRNA 2 antisense 
oligo: r(TAA GAT GTG AGA TTT CAG G)dTdG. The cells were trypsinized 24 hours post-
transfection and seeded for further analysis as described below. The remaining cells were 
seeded into a 6-well plate and cultured for an additional 48 hours for determination of 
knockdown efficiency.  
 
Reverse transcription. 
 YY1, CDC6, and MCM5 transcript levels were determined using quantitative real time 
PCR (TaqMan Assays on Demand, Assay IDs: Hs00231533_m1, Hs00154374_m1, 
,Hs00198823_m1, respectively; Applied Biosystems) after generation of oligo dT primed cDNA 
using Superscript II reverse transcriptase (Invitrogen). Initial experiments showed that siRNA-
mediated knockdown of YY1 also variably affected the expression of ß2-Microglobulin, intended 
as a control for input RNA normalization (TaqMan Assays on Demand, Assay ID 
Hs00187842_m1). All reverse transcription reactions were performed with one μg of total RNA 
as input measured on a Nanodrop 1000 spectrophotometer (Thermo Scientific; Wilmington, 
DE). We therefore directly utilized cycle threshold values for all assessments of YY1 mRNA 
levels in real time RT-PCR experiments, which were performed at least in duplicate.   
 
Western blotting. 
 Hey and BG1 cells were transiently transfected in two independent experiments with 
YY1 siRNA or control non-silencing siRNA as described above and incubated for 48 or 72 hours 
prior to harvesting.  Whole cell lysates were prepared using Biosource NP40 cell lysis buffer 
(Invitrogen). Proteins were resolved by SDS-PAGE (4-15%) and transferred to a nitrocellulose 
membrane (Biorad; Hercules, CA). A 1:200 dilution of mouse anti-human YY1 antibody (H-10) 
(sc-7341, Santa Cruz Biotechnology; Santa Cruz, CA) was used followed by detection with a 
1:3000 dilution of secondary antibody (Biorad) and the Enhanced Chemiluminescence system 
(Amersham Biosciences; Piscataway, NJ). Mouse anti-GAPDH antibody was used as an 
internal loading control.  
 
Cell proliferation assays.  
 103 BG1 or HEY ovarian cancer cells were seeded into individual wells of a 96-well plate 
containing 100 μl of culture medium followed by transfection with control or YY1-specific siRNA 
oligos in quadruplicate. 96 hours post-transfection, cell proliferation was measured using the 
CellTiter 96® AQueous One Solution Cell Proliferation Assay according to the manufacturer’s 
recommendations (Promega; Madison, WI). 
 
 
Anchorage-independent growth assays.  
 103 BG1 or HEY ovarian cancer cells were seeded into individual wells of a 96-well plate 
containing 0.5% agar / RPMI 1640 followed by transfection with control or YY1-specific siRNA 
oligos in quadruplicate. The cells were cultured for 7-10 days prior to counting colonies >100mm 
in diameter. 
 
Wound healing assays.  
  BG1 and HEY ovarian cancer cells were transfected with control and YY1-specific 
siRNA oligos in a 24-well plate as described above. 24 hours post-transfection, the cells from 
two wells were combined and seeded into one well of a 6-well plate. The cells reached near 
confluence (>90%) 72 hours after transfection. ‘Wounds’ were introduced through the cell 
monolayer at 72 hours post-transfection using a P-1000 pipet tip. The cells were gently rinsed 
with PBS and cultured in RPMI 1640 medium containing 10% FBS. Micrographs were taken at 
time 0 and at 5, 20, and 28 hours post-wounding using the 10× objective of an inverted phase 
contrast microscope. The line tool in Canvas 9 (ACDSee Systems; Miami, FL) was used on the 
digital image to measure the distance between the facing edges of the expanding cells within 
the gap at five roughly equidistant locations.   
 
Response to chemotherapy.  
 The in vitro cytotoxic effect of Cisplatin, Docetaxel and Paclitaxel (all obtained from 
Sigma-Aldrich; St. Louis, MO) were evaluated as previously described (26) in BG1 and HEY 
ovarian cancer cells. In brief, 2 X 104 cells that were transfected with control or YY1-specific 
siRNA oligos were treated with each drug for 24 hours beginning five hours post-transfection. 
The effect of treatment was measured using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay as described above. IC50 values (defined as 50% inhibition of cell 
proliferation) were calculated for each data point using GraphPad Prism 4 software (GraphPad 
Software, Inc.; San Diego, CA). Knockdown experiments, followed by chemosensitivity assays, 
were repeated ten times. 
 
Statistical analysis.  
 For ranking of genes with or without TRANSFAC motifs, the Mann-Whitney U test was 
performed. Ranking of genes with or without the Gene Ontology cellular component annotation 
of microtubule was also analyzed using the Mann-Whitney U test and chi square tests where 
 appropriate. Survival comparison was performed using a Logrank test. Paired t-tests were used 
to compare IC50 values between control and YY1 siRNA treated samples. Deviation of 
borderline tumors among clusters was calculated using Fisher's exact test. IC50 value 
differences between clusters in the NCI60 dataset were calculated using Mann-Whitney U tests. 
For these calculations, GraphPad Prism 4.0b software was used. The enrichment of Gene 
Ontology terms for ‘biological process’ was analyzed using GATHER (22). For other statistical 
analyses, two-tailed student’s t-tests were used. P values <0.05 were considered significant.
 RESULTS 
 
Comparison of YY1 microarray expression with RT-PCR data, immunohistochemistry, 
and CGH arrays and potential epigenetic regulation. 
 Our prior microarray-based analysis of stage III-IV serous epithelial ovarian cancer 
specimens showed that YY1 was one of the most differentially expressed genes that 
distinguished long-term (>7 years) from short-term (<3 years) survivors (1).  We validated the 
accuracy of the microarray expression levels of YY1 for 40 of these ovarian tumor specimens 
using quantitative real time RT-PCR (Figure S1A; r = -0.57, p=0.0001). We also examined YY1 
expression by immunohistochemistry to verify expression in tumor cells and correlate this with 
mRNA expression. Expression of YY1 protein ranged from very low to very high, with 
localization of YY1 in the nucleus, as expected for this DNA binding protein.  Higher nuclear 
YY1 expression in tumor cells was indeed associated with higher mRNA expression as detected 
by microarrays (r = 0.35, p=0.04, representative staining shown in Figure S1B).  
 
To discern a cause for the differential expression of YY1 in ovarian cancer with regard to 
survival, we investigated the possibility of genetic and/or epigenetic alterations at this locus in 
these cases.  Chromosomal copy number changes are a frequent event in ovarian cancer and 
have been reported for the q arm of chromosome 14 where YY1 is located (23-25).  Such copy 
number changes might explain the differences in YY1 expression observed between long and 
short term survivors.  Comparative genomic hybridization (CGH) data was available for the 
majority of the ovarian tumors in our microarrayed dataset (unpublished data).  We found that 
there is a significant relationship between the level of YY1 expression detected by microarray 
analysis and the normalized signal intensities obtained for each of the genomic clones 
represented on the CGH arrays present at 14q32, evident for multiple 14q32 probes (Figure 
S1C).  Promoter methylation and genomic imprinting were also analyzed for YY1, to explore 
 other possibile explanations for decreased expression in women with ovarian cancer living less 
than 3 years versus those living greater than seven years. Imprinting of YY1 is plausible 
because of its location adjacent to a known imprinted cluser at 14q32 (Figure S2A).  However, 
YY1 was not imprinted (Figures S2B and S2C), nor was the YY1 promoter CpG island subject 
to aberrant methylation in ovarian cancers (Figure S3). 
  
Positive correlation between YY1 expression and expression of genes containing YY1 
and E2F binding motifs in ovarian tumors. 
 Gene expression correlations obtained from microarray data in isolation cannot define 
cause and effect relationships between gene transcripts. However, when gene expression data 
is coupled with transcription factor binding motif analysis, a relationship between effector and 
target can be inferred, especially when the effector regulates the transcription of other target 
genes. YY1 is known to have ubiquitous target sites, and to exert diverse effects on the 
transcription of downstream target genes. Our previously generated microarray dataset (1) was 
therefore analyzed for correlations in expression between YY1 and genes positive for putative 
YY1 binding motifs (V$YY1_Q6, V$YY1_01 and V$YY1_02). Annotations for microarray probes 
were generated using the TRANSFAC database (19). We first ranked the expression values for 
the Affymetrix U133A probes (n=22,215) by their correlation to the expression value of the YY1 
probes and then created annotations for all Affymetrix probes that contain YY1 binding motifs. 
The results show that genes with YY1 binding motifs are significantly enriched among all genes 
showing positive correlation to YY1 (p<0.0001 for each motif; results for V$YY1_Q6 shown in 
Figure 1A). This strongly suggests that YY1 primarily upregulates the expression of genes 
containing YY1 binding motifs in ovarian tumors.  
 
 Analysis of Gene Ontology (GO) terms (26) for the top 500 YY1-positively correlated 
genes with YY1 binding motif(s) using the web-based tool GATHER [Gene Annotation Tool to 
 Help Explain Relationships; (22)] showed enrichment of cell cycle-related GO terms (e.g. 
GO:0007049: cell cycle, GO:0007067: mitosis; p<0.0001, respectively). Furthermore, 
transcription factor E2F binding motifs were increased in this group of genes based on GATHER 
(data not shown). We therefore turned our attention to the relationship between YY1 and E2F. 
Among the U133A probes with an annotation for YY1 binding motifs (V$YY1_Q6, n=4,749), 
expression of genes with transcription factor E2F binding motifs (V$E2F_Q2, V$E2F1_Q3, 
V$E2F_Q6, V$E2F1_Q6, V$E2F_Q4, and V$E2F1_Q6_01) were also positively correlated to 
the expression of YY1 in ovarian tumor tissue (motif positive versus motif negative, Mann-
Whitney U test; p<0.0001 for each site; results for V$E2F1_Q3 shown in Figure 1B). The 
positive correlation of all three YY1 binding motifs with YY1 expression, together with the 
presence of E2F sites among these genes suggests that YY1 upregulates expression of genes 
that contain both YY1 and E2F binding motifs. 
 
Clustering of ovarian tumors by YY1-positively correlated, YY1 and E2F site-containing 
genes. 
 To better understand the relationship in ovarian cancer between tumor phenotype and 
YY1-correlated genes, we performed hierarchical clustering, using the top 250 YY1-positively 
correlated genes that contain YY1 and E2F binding motifs (V$YY1_Q6 and V$E2F1_Q3, 
respectively) and for which RMA-normalized expression values exceeded 7 in at least one 
tumor. We again found that cell cycle related GO terms were significantly enriched in this gene 
set (Table  SI). Clustering of the ovarian tumors based on the expression of these 250 genes 
created two groups: the ‘YY1 Low’ cluster and the ‘YY1 High’ cluster (Figure 1C). The clusters 
are based on the low and high expression levels, respectively, of the constituent genes. Since 
E2F binding motifs characterize this gene set, we also examined the probability of the presence 
of the recently defined E2F3 gene signature (16) in each ovarian tumor. The predicted 
probability for having the E2F3 signature positively correlates with the expression of YY1 
 (r=0.59, p<0.0001, not shown) and was significantly different between the YY1 Low and YY1 
High gene clusters (p<0.0001; Figure 1C, bottom). All ovarian borderline tumors were localized 
within the YY1 Low cluster (p<0.0001, Fisher’s exact test) and also had very low probabilities of 
gene expression profiles constituting the E2F3 gene signature. These results show that  the 
expression of putative YY1 target genes in ovarian cancer positively correlates with the 
probability of the tumor having an E2F3 gene signature.  
 
 Long-term survivors of advanced stage ovarian cancer clustered primarily with the 
tumors exhibiting higher expression of putative YY1 target genes, although this clustering was 
not statistically significant (median survival: 31 months versus 86 months). Different 
chemotherapeutic regimens were used among these patients, largely due to the addition of 
paclitaxel to the standard regimen only ten years ago (27, 28). We therefore restricted our 
analysis to patients who had received the current standard regimen consisting of paclitaxel and 
platinum to determine the influence of the YY1 signature on patient survival. Survival was only 
improved in the YY1 High cluster versus the YY1 Low cluster when primary ovarian cancer 
patients received chemotherapy that included paclitaxel (p=0.016; Figure 1D, left). In contrast, 
survival of primary ovarian cancer patients who did not receive paclitaxel was no different 
between the YY1 High and YY1 Low clusters. (p=0.47; Figure 1D, right).  
 
To provide additional evidence that the 250 probes identified from our analysis represent 
putative downstream target genes for YY1, we analyzed an additional external microarray 
dataset consisting of 79 ovarian cancer specimens (2). In agreement with our initial results, 
genes with YY1 binding motifs were significantly enriched in positive correlation with YY1 in the 
validation dataset (V$YY1_Q6; p<0.0001, V$YY1_01;p=0.005, V$YY1_02; p<0.0001). Among 
V$YY1_Q6(+) genes, E2F binding motifs were also enriched in positive correlation with YY1 (for 
V$E2F_Q2, V$E2F1_Q3, V$E2F1_Q6, V$E2F_Q6, V$E2F1_Q6_01, and V$E2F_Q4;  
 p<0.0001 for all). Next, we analyzed the validation set using the same 250 probes generated 
from the initial analysis.  These 250 probes also showed strong positive correlation with YY1 in 
the external dataset (not shown; p<0.0001). Hierarchical clustering with respect to the 250 
probes in the external dataset again generated two clusters with low and high expression of 
YY1 and putative YY1 target genes (p<0.0001, Figure S4A). Survival analysis indicated that 
patients in the “YY1 High cluster” who were treated with paclitaxel showed improved survival as 
compared to the other groups (p=0.010, Figure S4B). Comparison of survival among “YY1 High” 
versus “YY1 Low” tumors from patients treated with paclitaxel shows improved survival of 
patients in the “YY1 High” group, but this did not quite reach statistical significance (p=0.14). 
Nevertheless, these findings demonstrate reproducibility between ovarian cancer datasets in 
detecting associations among YY1, its putative downstream targets, and survival of patients 
treated with or without paclitaxel. 
 
Relationship between chemotherapeutic sensitivity and YY1-positively correlated genes 
among cancer cell lines in the NCI60 database. 
 To further validate our findings and determine if the association between YY1 expression 
and taxane response was present in other types of cancer cells, we analyzed the NCI60 cell line 
data.  The NCI60 database consists of a panel of 59 establlished cancer cell lines from multiple 
tissue types, with accompanying Affymetrix U95Av2 microarray data, for which pharmacologic 
response data has been generated for over 40,000 tested compounds (29). As we had found for 
ovarian cancer, when all probes (n=12,558) were sorted based on correlation to the expression 
level of YY1, V$YY1_Q6, V$YY1_01 and V$YY1_02 motif-positive genes were significantly 
enriched among genes with positive correlation to YY1 (for V$YY1_Q6 and V$YY1_01, 
p<0.0001; for V$YY1_02, p=0.0004; data for V$YY1_Q6 shown in Figure 2A).  
 
  Further analysis of the NCI60 dataset revealed other similarities to the results obtained 
with the ovarian cancer microarray data. For example, among the U95Av2 probes with an 
annotation for YY1 binding motifs (V$YY1_Q6, n=2,537), expression of genes with E2F binding 
motifs (V$E2F_Q2, V$E2F1_Q3, V$E2F_Q6, V$E2F1_Q6, V$E2F_Q4, and V$E2F1_Q6_01) 
was found to also be positively correlated to the expression of YY1 (p<0.0001 for each site; 
result for V$E2F1_Q3 shown in Figure 2B). Gene Ontology terms for this subgroup of genes 
(YY1- and E2F-site positive genes in positive correlation with YY1) also showed striking 
resemblance between the ovarian cancers and NCI60 cell lines, including cell cycle terms 
(Table  SII).  
 
 Clustering was performed by taking the top 150 YY1-positively correlated probes with 
both YY1 and E2F binding motifs from the NCI60 dataset and dividing the genes into YY1 High 
and YY1 Low clusters. Supporting our results for the primary ovarian cancers, the NCI60 cancer 
cell lines in the YY1 High cluster were more sensitive to Paclitaxel and Docetaxel than cell lines 
in the YY1 Low cluster (Figure 2C). On the other hand, sensitivity to Cisplatin and Carboplatin, 
both platinum-based drugs, did not differ between the cell lines in these clusters.  
  
Effect of YY1 knockdown on ovarian cancer cell behavior. 
 To better understand the function of YY1 in ovarian cancer, we used siRNA-mediated 
knockdown to suppress YY1 expression followed by assays to measure the effect on cell 
phenotype in ovarian cancer cell lines. Transcriptional suppression was confirmed to be ~90% 
or greater with two independent siRNA oligos as compared to YY1 expression using a non-
silencing siRNA oligo (Figure 3A, left panel), and this suppression was maintained at least 
through 96 hours post-transfection (not shown). That transcriptional repression was achieved 
with two independent siRNA oligos supports specificity of the effect to YY1.  Western blotting 
 showed that YY1 protein expression was also repressed as a result of siRNA-mediated 
knockdown of YY1 (Figure 3A, right panel).  
  
 YY1 knockdown led to a significant reduction in cell proliferation using both YY1-specific 
siRNA oligos in HEY (p=0.03 and p=0.003, respectively) and BG1 cells (p<0.0005 for both 
oligos; Figure 3B). YY1 knockdown affected reduced expression of CDC6, an established 
YY1/E2F target gene (12), and MCM5, a putative YY1/E2F target gene (10, 30) (Figure 3C). 
YY1 knockdown also resulted in suppression of anchorage-independent growth in BG1 and 
HEY cells (p=0.002 and p=0.001, respectively; Figure 3D) although these results may reflect the 
reduced proliferative capacity also induced by YY1 suppression (refer to Figure 3B). 
Furthermore, YY1 suppression reduced the motility of BG1 and HEY cells as measured by their 
ability to fill in a gap induced by scraping a monolayer of cells with a pipet tip (Figure 3E; at 28 
hours, p=0.0007 and p=0.0006, respectively).  
 
 We then analyzed the effect of YY1 knockdown on response to Paclitaxel, Docetaxel 
and Cisplatin by calculating the 50% Growth Inhibitory (IC50) dose for each drug in the HEY 
and BG1 ovarian cancer cell lines.  The results for ten experiments each indicate that the IC50 
was significantly increased for HEY and BG1 cells with YY1 knockdown for both Paclitaxel 
(p=0.0005 and p=0.002, respectively) and Docetaxel (p=0.0007 and p=0.0004, respectively) 
(Figure 4A). However, YY1 knockdown did not alter sensitivity to Cisplatin in either cell line 
(p=0.52 and p=0.62, respectively) (Figure 4B).  
 
Transcriptional regulation of microtubule-related molecules by YY1/E2F3. 
 Given the increased sensitivity to microtubule stabilizing taxanes when YY1 expression 
is increased, we analyzed the relationship between microtubule-related molecules and 
YY1/E2F3 and the gene ontology annotations (cellular component) for “microtubule” (GO#5874)  
 and “microtubule associated complex” (GO#5875). Affymetrix probe annotations linking genes 
with these  GO terms were obtained from the Affymetrix web site (http://www.affymetrix.com). 
Among the 17,136 genes represented by the Affymetrix U133v2 54,613 probes, 150 genes 
have the annotation GO#5874 “microtubule” and 3,932 genes have the annotation for 
V$YY1_Q6. Overlap of the annotations for “microtubule” and YY1 binding motifs was 
statistically significant; 35% (53/150) of “microtubule” positive genes have YY1 binding motifs, 
as compared to 23% (3,879/16,986) of “microtubule” negative genes (p=0.0002, Chi square 
test). 69% (104/150) of genes with E2F binding motifs (V$E2F_Q2) also significantly overlapped 
with “microtubule” positive genes versus 61% for “microtubule” negative genes (10,341/16,986; 
p=0.035). Similarly, genes with a “microtubule associated complex” GO annotation (n=56) were 
more likely to have YY1 and E2F binding motifs versus those without (V$YY1_Q6: 27% vs. 
23%, V$E2F_Q2: 68% vs. 61%), although this was not statistically significant likely due to small 
sample size. 
 
 In order to examine if the expression of microtubule-related genes is associated with 
expression of YY1 and E2F3, we utilized recently published data in which the consequence of 
E2F3 overexpression in primary mammary epithelial cells was analyzed by gene expression 
microarray (16). Using Gene Set Enrichment Analysis (GSEA), we found that genes with GO 
annotations “microtubule” (GO#5874) and “microtubule associated complex” (GO#5875) were 
significantly enriched in cells overexpressing E2F3 (Figures S5A and B, FDR=0.160 and 
FDR=0.205, respectively). We then examined our primary ovarian cancer microarray data and 
found that the Affymetrix U133A gene probes with these same microtubule-related GO 
designations were significantly enriched among genes positively correlated to YY1 (Figure S5C, 
GO#5874 “microtubule” p=0.004; GO#5875 “microtubule associated complex” p=0.012, Mann-





 Gene expression correlations obtained from microarray data in isolation cannot define 
cause and effect relationships between gene transcripts. However, when gene expression data 
is combined with transcription factor binding motif analysis, a relationship between effector and 
target can be inferred, especially when the effector regulates the transcription of other target 
genes. YY1 is known to have ubiquitous target sites, and to exert diverse effects on the 
transcription of downstream target genes, depending on the nature of YY1 interactions with 
cofactors and its target sequence. We have shown here that YY1 expression positively 
correlates with the expression of genes containing YY1-binding motifs in their promoter region in 
our ovarian cancer datasets, an external ovarian cancer dataset and in the NCI60 dataset. 
These results strongly suggest that YY1 upregulates these putative downstream target genes in 
cancer. However, this seems to differ with the known role of YY1 as both a transcriptional 
enhancer and suppressor of its downstream targets (9), since we did not find enrichment of YY1 
binding motif-positive genes in negative correlation with YY1. This may be due to insufficient 
number of negatively regulated genes to detect by statistical analyses amid the background of 
the genome, or conversely, it may suggest that in cancer cells, the primary function of YY1 is to 
upregulate the expression of select target genes. These explanations are not mutually 
exclusive. Regardless, our results from analysis of the tumor microarrays and transcription 
factor binding motifs detected only YY1-correlated upregulation. 
 
 YY1 was previously shown to function synergistically with E2F2 and E2F3 to activate 
target gene transcription in a molecular complex bridged by the Ring1- and YY1-binding protein 
(RYBP) (12). Our results support that YY1 and E2F3 work together in regulating gene 
expression in ovarian cancer and among the NCI60 cancer cell lines.  Experimentally, YY1 is 
known to deregulate the cell cycle in cancer cells (9). Using siRNA-mediated knockdown of YY1 
 in ovarian cancer cells, we found that suppression of YY1 leads to a reduction in cell 
proliferation. We therefore considered that YY1, along with coactivator E2F, have a stimulatory 
effect on the cell cycle in this setting. We thus designated genes having both YY1 and E2F 
binding-motifs that were positively correlated with YY1 expression as putative YY1 target genes. 
 
 Clustering by the putative YY1 target genes clearly divided ovarian cancer into two 
distinct groups, and the expression of genes within these groups strikingly correlated with an 
independent gene expression profile that was generated by overexpressing E2F3 (23). This 
lends additional support to the idea that there is a strong association between YY1 and E2F 
activity in ovarian cancer. Further evidence of this association comes from our finding that 
borderline tumors, known to have low proliferative activity (31), are characterized by low 
expression of putative YY1 downstream target genes and low E2F3 activity.  
 
In spite of the propensity of YY1/E2F to increase oncogenic behavior of cells in vitro, we 
found that a poorer prognosis among primary ovarian cancer patients was evident in the YY1 
Low cluster rather than in the YY1 High cluster. In support of this, association between poor 
prognosis and low proliferative activity was previously shown in ovarian cancer (32-34). In the 
current study, the difference in prognosis for YY1 High versus YY1 Low clusters was statistically 
significant only in the group of patients treated with paclitaxel. Hence, prognoses may be 
determined by the ability of YY1 to modulate chemotherapeutic response, with high YY1 
expression working to enhance the effectiveness of the drug through modulation of its 
downstream targets.  
 
 In order to further evaluate a potential role for YY1 in affecting chemotherapeutic 
response, we analyzed the NCI60 dataset. Correlations between YY1 expression and genes 
with YY1 and E2F binding motifs in the NCI60 dataset were the same as those we observed in 
 ovarian cancer, and gene ontology terms of the putative YY1 target genes among the NCI60 
cell lines also largely mimicked those in ovarian cancer.  This indicates similarity of biological 
roles of YY1 in ovarian cancer and in the NCI60 cancer cell lines. Because of these shared 
features, we compared the survival of ovarian cancer patients with respect to chemotherapeutic 
treatment with the chemotherapeutic responses observed in the NCI60 cancer cell lines. 
 
 When the NCI60 cells were divided into two groups based on the expression of YY1/E2F 
putative target genes, the YY1 High cluster exhibited increased sensitivity to taxanes, but not to 
platinum based drugs. This result is similar to the ovarian cancer data in that the improved 
prognosis of ovarian cancer patients treated with paclitaxel is associated with the elevated 
expression of putative YY1/E2F downstream genes. These data strongly implicate YY1/E2F as 
an effector of response to taxane-based chemotherapeutic agents. This was confirmed with our 
finding that YY1 knockdown reproducibly increases resistance to both paclitaxel and docetaxel, 
but not to cisplatin in ovarian cancer cell lines. This result is further supported by a previous 
report showing that overexpression of E2F increases sensitivity to paclitaxel but not to cisplatin 
(35).  
 
 The reasons underlying the association between taxane sensitivity and higher YY1/E2F 
activity remains unclear. As taxane specifically targets microtubules, the mechanism(s) of 
sensitivity could be related to microtubule function (36). Our finding that knockdown of YY1 
suppressed both proliferation and migration negates our hypothesis that YY1 functions as a 
tumr suppressor, but supports the notion that YY1/E2F have a role in regulating microtubule 
function, since migration is known to have a strong association with microtubule dynamics (37). 
Several additional lines of evidence also suggest that YY1/E2F have a regulatory role in 
directing the transcription of proteins involved in microtubule dynamics, including 1) our 
computational analysis showing the increased expression of genes with YY1 and E2F binding 
 motifs that comprise the microtubule-related Gene Ontology data sets, 2) upregulation of 
microtubule-related genes by overexpression of E2F3, and 3) positive correlation between the 
expression of microtubule-related genes and YY1 in ovarian cancer. It is not clear whether 
transcriptional upregulation of many microtubule-related genes by YY1/E2F caused taxane-
specific sensitivity or not. However, our results may provide the foundation and impetus for 
further investigation of microtubule function and relationship to YY1 to determine the 
mechanistic basis of taxane sensitivity in YY1 High tumor cells. 
 
 In conclusion, we have used gene expression data from microarrays to elucidate 
molecular mechanisms involved in chemosensitivity. We found that YY1, in association with 
E2F, upregulates downstream genes in ovarian cancer. A “YY1 High” gene signature is 
associated with improved prognosis in ovarian cancer when patients are treated with taxanes. 
We also showed that high YY1 activity results in increased sensitivity to taxanes in vitro. These 
findings may be clinically applicable in distinguishing taxane-sensitive patients from taxane-
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 FIGURE LEGENDS 
 
Figure 1. YY1 target genes in ovarian cancer.  
(A) Genes whose expression is correlated with that of YY1 are enriched in binding motifs for 
YY1. Color bar represents all Affymetrix U133A probes with a RefSeq annotation arranged by 
their correlation to the expression of YY1 using the expression values from 88 ovarian tumors. 
Black and white bar represents the same distribution of probes, where a single black horizontal 
line indicates the presence of an YY1 binding motif (V$YY1_Q6) for that gene. (B) Among 4,749 
genes that contain the V$YY1_Q6 binding motif, genes whose expression is correlated with that 
of YY1 are enriched for E2F binding motifs (V$E2F1_Q3). (C) Clustering by putative YY1 target 
genes in ovarian tumors. The top 250 YY1-positively correlated genes were selected for 
clustering based on 1) the presence of both YY1 (V$YY1_Q6) and E2F (V$E2F1_Q3) binding 
motifs and 2) having at least one tumor with relatively high level expression of the gene (RMA 
normalized value >7). The ‘YY1 Low’ and ‘YY1 High’ clusters are characterized by low and high 
expression, respectively of YY1 and YY1-correlated genes. Color bar below the heat map, 
probability of having an ‘E2F3 signature’. (D) Kaplan-Meier analysis of primary ovarian cancer 
patients who received platinum and did (left; N=36) or did not (right; N=28) receive paclitaxel. 
Patients are stratified based on the assignment of their tumor to the ‘YY1 Low’ or ‘YY1 High’ 
cluster.  
 
Figure 2. YY1 target genes in the NCI60 cell lines.  
(A) Genes whose expression is correlated with that of YY1 are enriched in binding sites for YY1. 
Color bar represents all U95Av2 probes with a RefSeq annotation arranged by their correlation 
to the expression of YY1 using the expression values from the NCI60 cell lines. Black and white 
bar represents the same distribution of probes, where a single black horizontal line indicates the 
presence of an YY1 binding motif (V$YY1_Q6) for that gene. (B) Among 2,537 genes that 
 contain YY1 binding motifs, genes whose expression is correlated with that of YY1 are enriched 
for E2F binding sites (V$E2F1_Q3). (C) Heatmaps showing expression of putative downstream 
target genes of YY1 (bottom) and relation to taxane sensitivity in the NCI60 dataset (top). The 
top 150 YY1-positively correlated genes (Affymetrix U95Av2) were analyzed that contain both 
YY1 (V$YY1_Q6) and E2F (V$E2F1_Q3) binding motifs and that have at least one cell line with 
a log2(MAS5) expression value ≥7. Columns, individual cell lines; rows, individual gene probes. 
Cell lines (left to right): SNB-75, U251, A498, SF-295, UACC-62, SN12C, UO-31, 786-0, SNB-
19, OVCAR-3, OVCAR-4, SK-MEL-28, UACC-257, RXF-393, SF-268, DU-145, SKOV-3, 
IGROV1, MALME-3M, OVCAR-8, SK-MEL-5, HOP-92, CAKI-1, TK-10, PC-3, T-47D, OVCAR-5, 
HCT-116, KM12, SW-620, HCT-15, MCF7, HT29, NCI-H226, MOLT-4, CCRF-CEM, NCI/ADR-
RES, MDA-MB-231/ATCC, HCC-2998, A549/ATCC, NCIH522, NCI-H23, LOX IMVI, NCI-H460, 
EKVX, NCI-H322M, SK-MEL-2, SR, BT-549, HS 578T, SF-539, HOP-62, M14, MDA-MB-435, 
COLO 205, HL-60(TB), ACHN, RPMI-8226 and K-562. The ‘YY1 Low’ and ‘YY1 High’ clusters 
are indicated above the heat map. The four colored rows above the heat map represent GI50 
values for (top to bottom) paclitaxel, docetaxel, cisplatin and carboplatin. Blue, resistant; red, 
sensitive. 
 
Figure 3. Effect of YY1 knockdown on ovarian cancer cell behavior.  
(A, left) Efficiency of siRNA-mediated knockdown of YY1. Cells were transfected with control 
non-silencing siRNA oligos (C) or with two independent siRNA oligos specific to YY1 (1 and 2). 
Quantitative real-time RT-PCR assays were performed in duplicate and are shown for 72 hours 
post-transfection. Y-axis, expression (+SEM) relative to that of the control. (A, right) Western 
blotting of HEY and BG1 cells transfected with control or YY1-specific siRNAs at 48 and 72 
hours post-transfection.  GAPDH, endogenous control. (B) siRNA-mediated knockdown of YY1 
inhibits cell proliferation. Y-axis, mean absorbance (+SEM) at 490 nm at 72 hours post-
transfection. (C) Suppression of YY1/E2F target genes CDC6 and MCM5 measured by 
 quantitative RT-PCR following knockdown of YY1. (D) Knockdown of YY1 inhibits anchorage-
independent growth. Results are shown (+SEM) for 2X103 seeded cells per well; proportional 
results were obtained when 5X103 cells were seeded per well. (E) Knockdown of YY1 inhibits 
migration in wound healing assays. Photomicrographs were taken at the indicated time points 
following wounding.  
 
Figure 4. Knockdown of YY1 leads to increased resistance to paclitaxel and docetaxel (A), but 
not to cisplatin (B) in ovarian cancer cell lines.  
 
  




